ATLANTA--(BUSINESS WIRE)--Altea Therapeutics announces positive clinical results from Phase 1 human clinical studies for its basal insulin transdermal patch showing efficient, sustained and constant delivery of insulin at therapeutic levels. These results were presented this week at the 11th Annual Drug Delivery Partnerships Conference held in Las Vegas, Nevada.
